ProRx Pharma
ProRx Pharma is a 503B outsourcing facility based in Exton, PA. A government record names semaglutide and tirzepatide at ProRx Pharma; the newest is an FDA warning letter dated April 7, 2026. It fills prescriptions; it doesn’t write them, so you can’t get a GLP-1 from ProRx Pharma without a prescription from a licensed clinician.1
How to get a GLP‑1 filled by ProRx PharmaChecked November 20, 2026 against FDA, CMS and state board records. Every fact links to its source.
ProRx Pharma at a glance
How to get a GLP‑1 filled by ProRx Pharma
To get a GLP‑1 from ProRx Pharma, you first need a prescription: it fills prescriptions; it doesn’t write them or sell without one. An online program takes you through the steps: you fill in a health questionnaire, a licensed clinician reviews it, and if they prescribe, the program’s pharmacy ships the medication to you.
These are the three programs ranked highest on our score. Check that a program ships to your state before you sign up.
- 1Health questionnaire, online
- 2A licensed clinician decides
- 3The pharmacy ships to you
We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money
Prefer your own clinician? You’re free to: ask them to send your prescription to ProRx Pharma or another licensed pharmacy.
See every program we rankWhat ties ProRx Pharma to GLP‑1s
- FDA warning letterApril 7, 2026 · semaglutide and tirzepatideFDA warning letter WL # 723704 to ProRX LLC3
“Your facility compounded drug products using tirzepatide bulk drug substance.”
- FDA recallOctober 15, 2025 · semaglutideClass II recall D-0115-2026: Lack of Assurance of Sterility4
“Semaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-04”
- FDA recallOctober 15, 2025 · semaglutideClass II recall D-0116-2026: Lack of Assurance of Sterility5
“Semaglutide Injection, 6mg/2.4mL (2.5 mg/mL), 2.4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-08”
- FDA recallOctober 15, 2025 · semaglutideClass II recall D-0118-2026: Lack of Assurance of Sterility6
“Semaglutide Injection, 2.5mg/1mL (2.5 mg/mL), 1mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-06”
- FDA recallOctober 15, 2025 · semaglutideClass II recall D-0117-2026: Lack of Assurance of Sterility7
“Semaglutide Injection, 8mg/3.2mL (2.5 mg/mL), 3.2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-09”
- FDA recallOctober 15, 2025 · semaglutideClass II recall D-0114-2026: Lack of Assurance of Sterility8
“Semaglutide Injection, 12.5/5mL (2.5 mg/mL), 5mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-09”
- FDA recallOctober 15, 2025 · semaglutideClass II recall D-0119-2026: Lack of Assurance of Sterility9
“Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-02”
- FDA recallOctober 15, 2025 · tirzepatideClass II recall D-0120-2026: Lack of Assurance of Sterility10
“Tirzepatide Injection, 27 mg/3 mL (9 mg/mL), 3mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-209-03”
- FDA inspection report (Form 483)September 19, 2025 · semaglutide and tirzepatideFDA Form 483 inspectional observations, ProRX LLC, issued 2025-09-1911
“Semaglutide 5 mg/2 mL, Lot# PRORX052125-4”
- FDA warning letterMarch 4, 2025 · semaglutide and tirzepatideFDA warning letter WL # 696742 to ProRX LLC12
“Your facility’s drug products, such as Semaglutide 5mg/2ml (2.5mg/ml) 2ml, Tirzepatide 60mg/3ml (20mg/ml) 3ml, and Vancomycin 25mg/ml 10ml”
- FDA recallAugust 22, 2024 · semaglutideClass II recall D-0650-2024: Lack of Assurance of Sterility13
“Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass vial, ProRx, 267-565-7008, NDC 84139-225-01”
- FDA recallAugust 22, 2024 · semaglutideClass II recall D-0654-2024: Lack of Assurance of Sterility14
“Semaglutide / Cyanocobalamin Injection: 2.5/0.5 mg/mL, 2 mL Multiple Dose Vial, Compounded Rx Product, ProRX 267-565-7008, NDC 84139-225-02”
- FDA recallAugust 22, 2024 · semaglutideClass II recall D-0652-2024: Lack of Assurance of Sterility15
“SEMAGLUTIDE 5mg/2mL (2.5mg/mL), Rx Only 2 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-01”
- FDA recallAugust 22, 2024 · semaglutideClass II recall D-0653-2024: Lack of Assurance of Sterility16
“SEMAGLUTIDE 10mg/4mL (2.5mg/mL), 4 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-04”
- FDA recallAugust 22, 2024 · tirzepatideClass II recall D-0651-2024: Lack of Assurance of Sterility17
“Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product, ProRx 267-565-7008, NDC 84139-210-01”
- FDA recallAugust 22, 2024 · tirzepatideClass II recall D-0656-2024: Lack of Assurance of Sterility18
“TIRZEPATIDE 60 mg/3mL (20/mg/mL), Rx Only, 3mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-02”
- FDA recallAugust 22, 2024 · tirzepatideClass II recall D-0655-2024: Lack of Assurance of Sterility19
“TIRZEPATIDE 20 mg/2mL (10/mg/mL), Rx Only, 2mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-01”
- FDA inspection report (Form 483)August 2, 2024 · semaglutide and tirzepatideFDA Form 483 inspectional observations, ProRX LLC, issued 2024-08-0220
“uncapped filled vials of Semaglutide 2.5 mg/ml”
ProRx Pharma’s FDA record
| Date | What the FDA did |
|---|---|
| April 7, 2026 | Warning Letter Issued 04/07/20263 |
| September 19, 2025 | 483 Issued 09/19/202521 |
| March 4, 2025 | Amended Warning Letter Issued 03/04/202522 |
| August 2, 2024 | 483 Issued 08/02/202423 |
What a compounded GLP‑1 is, and what it isn’t
The bigger question with any compounded program is the drug itself. Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.2728 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.2624
ProRx Pharma: questions
- 1.ProRx Pharma: what it says it isprorxpharma.comretrieved 2026-11-20↩“As an FDA-Registered 503B Outsourcing Facility, ProRx does not dispense to patients.”
- 2.Registered Outsourcing FacilitiesU.S. Food and Drug Administrationretrieved 2026-11-20↩
- 3.FDA warning letter WL # 723704 to ProRX LLCFDAretrieved 2026-04-07↩“Your facility compounded drug products using tirzepatide bulk drug substance.”
- 4.Class II recall D-0115-2026: Lack of Assurance of SterilityU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-10-15↩“Semaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-04”
- 5.Class II recall D-0116-2026: Lack of Assurance of SterilityU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-10-15↩“Semaglutide Injection, 6mg/2.4mL (2.5 mg/mL), 2.4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-08”
- 6.Class II recall D-0118-2026: Lack of Assurance of SterilityU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-10-15↩“Semaglutide Injection, 2.5mg/1mL (2.5 mg/mL), 1mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-06”
- 7.Class II recall D-0117-2026: Lack of Assurance of SterilityU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-10-15↩“Semaglutide Injection, 8mg/3.2mL (2.5 mg/mL), 3.2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-09”
- 8.Class II recall D-0114-2026: Lack of Assurance of SterilityU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-10-15↩“Semaglutide Injection, 12.5/5mL (2.5 mg/mL), 5mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-09”
- 9.Class II recall D-0119-2026: Lack of Assurance of SterilityU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-10-15↩“Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-02”
- 10.Class II recall D-0120-2026: Lack of Assurance of SterilityU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-10-15↩“Tirzepatide Injection, 27 mg/3 mL (9 mg/mL), 3mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-209-03”
- 11.FDA Form 483 inspectional observations, ProRX LLC, issued 2025-09-19FDAretrieved 2025-09-19↩“Semaglutide 5 mg/2 mL, Lot# PRORX052125-4”
- 12.FDA warning letter WL # 696742 to ProRX LLCFDAretrieved 2025-03-04↩“Your facility’s drug products, such as Semaglutide 5mg/2ml (2.5mg/ml) 2ml, Tirzepatide 60mg/3ml (20mg/ml) 3ml, and Vancomycin 25mg/ml 10ml”
- 13.Class II recall D-0650-2024: Lack of Assurance of SterilityU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2024-08-22↩“Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass vial, ProRx, 267-565-7008, NDC 84139-225-01”
- 14.Class II recall D-0654-2024: Lack of Assurance of SterilityU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2024-08-22↩“Semaglutide / Cyanocobalamin Injection: 2.5/0.5 mg/mL, 2 mL Multiple Dose Vial, Compounded Rx Product, ProRX 267-565-7008, NDC 84139-225-02”
- 15.Class II recall D-0652-2024: Lack of Assurance of SterilityU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2024-08-22↩“SEMAGLUTIDE 5mg/2mL (2.5mg/mL), Rx Only 2 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-01”
- 16.Class II recall D-0653-2024: Lack of Assurance of SterilityU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2024-08-22↩“SEMAGLUTIDE 10mg/4mL (2.5mg/mL), 4 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-04”
- 17.Class II recall D-0651-2024: Lack of Assurance of SterilityU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2024-08-22↩“Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product, ProRx 267-565-7008, NDC 84139-210-01”
- 18.Class II recall D-0656-2024: Lack of Assurance of SterilityU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2024-08-22↩“TIRZEPATIDE 60 mg/3mL (20/mg/mL), Rx Only, 3mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-02”
- 19.Class II recall D-0655-2024: Lack of Assurance of SterilityU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2024-08-22↩“TIRZEPATIDE 20 mg/2mL (10/mg/mL), Rx Only, 2mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-01”
- 20.FDA Form 483 inspectional observations, ProRX LLC, issued 2024-08-02FDAretrieved 2024-08-02↩“uncapped filled vials of Semaglutide 2.5 mg/ml”
- 21.FDA: 483 Issued 09/19/2025U.S. Food and Drug Administration↩
- 22.FDA: Amended Warning Letter Issued 03/04/2025U.S. Food and Drug Administration↩
- 23.FDA: 483 Issued 08/02/2024 (PDF - 2.78 MB)U.S. Food and Drug Administration↩
- 24.Compounding inspections, recalls, and other actionsU.S. Food and Drug Administrationretrieved 2026-11-20↩
- 25.ProRx Pharma: where it shipsprorxpharma.comretrieved 2026-11-20↩“ProRx Pharma is Licensed to Ship To:”
- 26.Compounding and the FDA: Questions and AnswersU.S. Food and Drug Administration↩
- 27.
- 28.
A pharmacy’s record can change after the day we read it: check its license with its state board before you fill a prescription. An FDA document is an allegation or an observation the FDA has published, not a court finding. This page is educational and is not medical advice.